Once-in-a-Lifetime Hope as Personalized Vaccine Eradicates Advanced Kidney Cancer

March marks Kidney Health Awareness Month, highlighting advancements in kidney disease research. One such breakthrough comes from an early-phase trial conducted by Yale Cancer Center (YCC), where a personalized therapeutic vaccine generated a strong immune response in nine patients with advanced kidney cancer. The vaccine effectively eliminated the disease, and all participants remained cancer-free for approximately three years after treatment. Unlike preventive vaccines, therapeutic vaccines are designed to boost immunity after disease onset, aiming to modify its progression.

Tumor DNA and RNA to Target Cancer-Specific Mutations and Eliminate Remaining Cells Post-Surgery

Researchers designed each patient’s vaccine using genetic information from the patient’s tumor, analyzing DNA and RNA to identify cancer-specific mutations. Like all vaccines, personalized cancer vaccines (PCVs) train the immune system to recognize and eliminate threats; in this case, any remaining cancer cells after surgery. 

Currently approved immune therapies for kidney cancer enhance the immune system’s ability to attack cancer cells by “releasing the brakes” on immune responses. However, they do not guide immune cells to specific targets, which can limit their effectiveness for some patients and lead to side effects from an overactive immune response.

In the trial, the PCV was designed to target and eliminate specific mutated cells that drive tumor growth in patients with clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, accounting for 80% of cases. The standard treatment for ccRCC typically involves surgery to remove the tumor, followed by immunotherapy combined with targeted therapy.

“The idea behind this trial was to specifically steer the immune system toward a target that is unique to the tumor. For patients with high-risk ccRCC, we want to improve post-surgery treatment options that reduce the risk of the cancer coming back.” said David Braun, a researcher in YCC’s Center of Molecular and Cellular Oncology and assistant professor of medicine, pathology, and urology at Yale School of Medicine.

Tailored Vaccines Developed Using Tumor-Derived Neoantigens and Advanced DNA Sequencing

Doctors diagnose over 62,000 Americans with kidney cancer each year, making it one of the ten most common cancers in both men and women in the United States. Most cases occur in individuals between the ages of 65 and 74, with the risk increasing as people age.

During the study, researchers developed personalized vaccines for each of the nine patients using tumor tissue removed during surgery as a blueprint. They applied advanced DNA sequencing technology to identify specific molecular markers called neoantigens, found in cancer cells but absent in healthy tissue. Predictive algorithms then pinpointed the neoantigens most likely to trigger a strong immune response and incorporated them into the custom vaccines.

Administered after surgery, the vaccines trained the immune system to target and eliminate any remaining cancer cells while sparing healthy tissue. Patients typically experienced mild flu-like symptoms for one to two days, but none reported severe side effects. All nine patients developed an immune response within three weeks, and cancer-fighting T cells remained elevated throughout the study and for years afterward. In seven of the nine patients, these T cells were able to recognize the patient’s tumor.

Larger trials will confirm the vaccine’s effectiveness, building on the promising results. An ongoing Phase II study, NCT06307431, is now evaluating a similar PCV in combination with the targeted therapy Keytruda, also known as pembrolizumab. David Braun reemphasized by stating, “This strong and durable activation in T cells was encouraging and indicates that we’re able to generate a long-lasting, anti-cancer immune response with the vaccine.”

Related posts:

Weekly Top 5 in China (0217-0223) ESMO 2022: Promising Trials Highlights That Are Worth Following 2021 CSCO Highlights: JW Therapeutics, Innovent, Ambrx, HUTCHMED Release Latest Data on Cancer Drugs Key Trends in the Pharmaceutical Pipeline for 2024 — Part I: Transformative R&D Growth Driven by Breakthroughs in Oncology, Neurological, and Metabolic Therapies

Author

Denisse Sandoval